- Home
- NDLS vs LUMO Comparison
NDLS vs LUMO Comparison
Compare NDLS & LUMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- LUMO
- Stock Information
- Founded
- NDLS 1995
- LUMO 2011
- Country
- NDLS United States
- LUMO United States
- Employees
- NDLS N/A
- LUMO N/A
- Industry
- NDLS Restaurants
- LUMO Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- LUMO Health Care
- Exchange
- NDLS Nasdaq
- LUMO Nasdaq
- Market Cap
- NDLS 32.9M
- LUMO 37.4M
- IPO Year
- NDLS 2013
- LUMO N/A
- Fundamental
- Price
- NDLS $0.69
- LUMO $4.34
- Analyst Decision
- NDLS Strong Buy
- LUMO Buy
- Analyst Count
- NDLS 2
- LUMO 4
- Target Price
- NDLS $3.00
- LUMO $9.38
- AVG Volume (30 Days)
- NDLS 184.6K
- LUMO 133.0K
- Earning Date
- NDLS 11-06-2024
- LUMO 11-07-2024
- Dividend Yield
- NDLS N/A
- LUMO N/A
- EPS Growth
- NDLS N/A
- LUMO N/A
- EPS
- NDLS N/A
- LUMO N/A
- Revenue
- NDLS $495,817,000.00
- LUMO $2,205,000.00
- Revenue This Year
- NDLS N/A
- LUMO $184.11
- Revenue Next Year
- NDLS $0.14
- LUMO N/A
- P/E Ratio
- NDLS N/A
- LUMO N/A
- Revenue Growth
- NDLS N/A
- LUMO 26.94
- 52 Week Low
- NDLS $0.60
- LUMO $1.37
- 52 Week High
- NDLS $3.50
- LUMO $4.58
- Technical
- Relative Strength Index (RSI)
- NDLS 42.72
- LUMO 4.26
- Support Level
- NDLS $0.67
- LUMO $4.31
- Resistance Level
- NDLS $0.74
- LUMO $4.39
- Average True Range (ATR)
- NDLS 0.06
- LUMO 0.03
- MACD
- NDLS 0.02
- LUMO -0.44
- Stochastic Oscillator
- NDLS 60.00
- LUMO 0.00
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About LUMO Lumos Pharma Inc.
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.